Pyridine matrix metalloproteinase inhibitors

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MNT inhibiting amount of a compound of Formula II:

• 18
• or a pharmaceutically acceptable salt thereof,
• wherein R1 and R2 independently are hydrogen, halo, hydroxy., C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• and
• each R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted,
• n is an integer of from 0 to 6

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting amount of a compound of Formula III

• 19
• or a pharmaceutically acceptable salt thereof,
• wherein R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, CH2)n cycloalkyl, (CH2)n heteroaryl, wherein each CH2 is optionally substituted by one or more C1-C6 alkyl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S. or NH, and optionally substituted or unsubstituted;
• n is an integer of from 0 to 6.

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting amount of a compound of Formula IV

• 20
• or a pharmaceutically acceptable salt thereof.
• wherein n is 0 to 6,
• R1 and R2 independently are hydrogen, halo, hydroxy., C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF;3;
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, wherein each CH2 is optionally substituted by one or more C1-C6 alkyl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted, and
• R6, R7, R8, and R9 independently are hydrogen, halo, C1-C6 alkyl, C1-C6 alkoxy, nitro, or NH2.

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting amount of a compound of Formula V

• 21
• or a pharmaceutically acceptable salt thereof,
• wherein n is 0 to 6;
• R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;,
• Each Ar is independently aryl or Het, wherein aryl is phenyl or substituted phenyl;
• Het is an unsubstituted or substituted heteroaryl group.

A compound of Formula I

• 22
• or a pharmaceutically acceptable salt thereof,
• wherein
• R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• E is independently O or S
• A and B independently are OR4 or NR4R5,
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;I
• is an integer from 0 to 6.

A compound of Formula II

• 23
• or a pharmaceutically acceptable salt thereof,
• wherein R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• and
• each R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;
• n is an integer of from 0 to 6.

A compound of Formula III

• 24
• or a pharmaceutically acceptable salt thereof,
• wherein R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• Each R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, wherein each CH2 is optionally substituted by one or more C1-C6 alkyl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;
• n is an integer of from 0 to 6.

A compound of Formula IV:

• 25
• or a pharmaceutically acceptable salt thereof,
• wherein n is 0 to 6;
• R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, wherein each CH2 is optionally substituted by one or more C1-C6 alkyl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;I and p1 R6, R7, R8, and R9 independently are hydrogen, halo, C1-C6 alkyl, C1-C6 alkoxy, nitro, or NH2

A compound of Formula V:

• 26
• or a pharmaceutically acceptable salt thereof,
• wherein n is 0to 6;
• R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;
• Each Ar is independently aryl or Het, wherein aryl is phenyl or substituted
• Het is an unsubstituted or substituted heteroaryl group.

A compound selected from:

• Pyridine-2,4-dicarboxylic acid bis-(3-methoxy-benzylamide);
• Pyridine-3),5-dicarboxylic acid bis-(4-chloro-benzylamide);
• Pyridine-3 ,5-dicarboxylic acid bis-(3-chloro-benzylamide);
• 2-Methoxy-pyridine-3, 5-dicarboxylic acid bis-[(1,3-benzodioxol-5-ylmethyl) -amide];
• Pyridine-3 ,5-dicarboxylic acid bis-(1,3-benzodioxol-5-ylmethyl) ester,
• Pyridine-3,5-dicarboxylic acid bis-(4-methoxy-benzylamide),
• Pyridine-3,5-dicarboxylic acid bis-[(1,3-benzodioxol-5-ylmethyl)-amide],
• Pyridine-2,4-dicarboxylic acid bis-[(1,3-benzodioxol-5-ylmethyl)-amide],
• Pyridine-3,5-dicarboxylic acid bis-(4-fluoro-benzylamide);
• Pyridine-3,5-dicarboxylic acid, (4-chloro-benzylamide), [(1,3-benzodioxol -5 -ylmethyl)-amide],
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide), [( 1,3-benzodioxol -5-ylmethyl)-amide],
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide), (4-methoxy-benzylamide),
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide),(3-methoxy-benzylamide);
• Pyridine-3,5-dicarboxylic acid, (4-carbomethoxy-benzylamide), (3-methoxy-benzylamide);
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide),(3-pyridylmethylamide);
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide),(3-thiophenemethylamide);
• Pyridine-3,5-dicarboxylic acid, (2,1,3 -benzothiadiazol-5-ylmethyl) amide, [(1,3-benzodioxol-5-ylmethyl)-amide],
• Pyridine-3,5-dicarboxylic acid, (2,1,3 -benzooxadiazol-5-ylmethyl) amide, [(1,3-benzodioxol-5-ylmethyl)-amide],
• Pyridine-3,5-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, (4-methoxy-benzylamide).
• Pyridine-3,5-dicarboxylic acid, (2,1,3)-benzothiadiazol-5-ylmethyl) amide, (3-methoxy-benzylamide);
• Pyridine-3,5-dicarboxylic acid bis-(1,3-benzodioxol-5-ylmethyl) ester;
• 2-Methoxy-pyridine-3,5-dicarboxylic acid bis-[( 1,3-benzodioxol-5-ylmethyl)-amide],
• 2-Ethoxy-pyridine-3,5-dicarboxylic acid bis-[(1,3-benzodioxol-5-ylmethyl)-amide];
• 2-Oxo-1,2-dihydro-pyridine-3,5-dicarboxylic acid bis-benzylamide;
• 2-Methoxy-pyridine-3,5-dicarboxylic acid bis-benzylamide, (3,5-Bis-benzylcarbamoyl-pyridin-2-yloxy)-acetic acid tert-butyl ester,
• (3,5-Bis-benzylcarbamoyl-pyridin-2-yloxy)-acetic acid,
• Pyridine-2,4-dicarboxylic acid bis-(3-methoxy-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-[(1,3-benzodioxol-5-ylmethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(2,4-dimethoxy-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-(4-chloro-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-benzylamide;
• Pyridine-2,4-dicarboxylic acid bis-[(naphthalen-1-ylmethyl)-amide],
• Pyridine-2,4-dicarboxylic acid bis-[(2-p-tolyl-ethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(4-methoxy-benzylamide) ,
• Pyridine-2,4-dicarboxylic acid bis-(3)-fluoro-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-(benzyl-ethyl-amide);
• Pyridine-2,4-dicarboxylic acid bis-{[2-(3,4-dimethoxy-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-{[2-(2-phenoxy-phenyl)-ethyl]-amide},
• Pyridine-2,4-dicarboxylic acid bis-[(4-phenyl-butyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-{[2-(4-methoxy-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-{[2-(2-fluoro-phenyl)-ethyl]-amide},
• Pyridine-2,4-dicarboxylic acid bis-{[2-(3 )-chloro-phenyl)-ethyl]-amide},
• Pyridine-2,4-dicarboxylic acid bis-{[2-(2,4-dimethyl-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-[(2-o-tolyl-ethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-{[2-(4-ethyl-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-[(2-phenyl-propyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-[(1,2-diphenyl-ethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(2,4-dichloro-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-[(biphenyl-2-ylmethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(3-chloro-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(3,5-dimethoxy-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-(3,4-dimethoxy-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-(ethyl-pyridin-4-ylmethyl-amide);
• Pyridine-2,4-dicarboxylic acid bis-[(2-pyridin-4-yl-ethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-[(2-pyridin-3-yl-ethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-{[(2-pyridin-4-chloro-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-[(-pyridin-4-ylmethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(3.5-bis-trifluoromethyl-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-(2,3-dimethoxy-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(3-trifluoromethyl-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-(2-trifluoromethoxy-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(3-difluoromethoxy-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(2-difluoromethoxy-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(4-fluoro-3-trifluoromethyl-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(2-methoxy-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-{[2-(3-ethoxy-phenyl)-ethyl]-amide},
• Pyridine-2,4-dicarboxylic acid bis-(3-chloro-4-fluoro-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(2,4-difluoro-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-(4-amino-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-(2-methyl-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-{[(bis-(4-methoxy-phenyl)-methyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-[(3,3-diphenyl-propyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-[(1-methyl-3-phenyl-propyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-[(3,4-dimethoxy-phenyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(2-fluoro-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-[(3-imidazol-1-yl-propyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(2-chloro-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(2-trifluoromethyl-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-(4-methyl-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-{[2-(3-methoxy-phenyl)-ethyl]-amide},
• Pyridine-2,4-dicarboxylic acid bis-[(1-phenyl-ethyl)-amide],
• Pyridine-2,4-dicarboxylic acid bis-[(pyridin-3-ylmethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-[(4-ethoxy-phenyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(phenethyl-amide);
• Pyridine-2,4-dicarboxylic acid bis-[(thiophen-2-ylmethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-(4trifluoromethyl-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-[(5-methyl-furan-2-ylmethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-{[1-(4-fluoro-phenyl)-ethyl]-amide},
• Pyridine-2,4-dicarboxylic acid bis-(2-amino-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-[(1-naphthalen-1-yl-ethyl)-amide],
• Pyridine-2,4-dicarboxylic acid bis-{[2-(4-hydroxy-phenyl)-ethyl ]-amide};
• Pyridine-2,4-dicarboxylic acid bis-(3-trifluoromethoxy-benzylamide);
• Pyridine-2,4-dicarboxylic acid bis-{[1-(3-methoxy-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-[(1-phenyl-propyl)-amide],
• Pyridine-2,4-dicarboxylic acid bis-{[2-(2-methoxy-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-{[2-(3-trifluoromethyl-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-indan-1-ylamide,
• Pyridine-2,4-dicarboxylic acid bis-indan-1-ylamide;
• Pyridine-2,4-dicarboxylic acid bis-(3,4-dichloro-benzylamide),
• Pyridine-2,4-dicarboxylic acid bis-[(2-ethoxy-ethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-{[2-(4-bromo-phenyl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-[(2-pyridin-2-yl-ethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-[(2-thiophen-2-yl-ethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-{[2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide};
• Pyridine-2,4-dicarboxylic acid bis-{[2-(1H-indol-3-yl)-ethyl]-amide},
• Pyridine-2,4-dicarboxylic acid bis-(3,5-dichloro-benzylamide), and 2-Amino-pyridine-3,5-dicarboxylic acid bis-[(1,3 -benzodioxol-5 ylmethyl)-amide]

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering an MMP inhibiting amount of a compound of Formula I

• 27
• wherein:
• R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• E is independently O or S;
• A and B independently are OR4 or NR4R5,
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl., (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S,. or NH, and optionally substituted or unsubstituted
• n is an integer from 0 to 6;
• and the pharmaceutically acceptable salts thereof.

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering an MMP inhibiting amount of a compound of Formula II:

• 28
• wherein R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• and
• each R4 is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl,
• and the pharmaceutically acceptable salts thereof

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering an MMP inhibiting amount of a compound of Formula III:

• 29
• wherein R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3,
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;
• and the pharmaceutically acceptable salts thereof.

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering an MMP inhibiting amount of a compound of Formula IV:

• 30
• wherein n is 0 to 6;
• R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• and R6, R7, R8, and R9 independently are hydrogen, halo, C1-C6 alkyl, C1-C6 alkoxy, nitro, or NH2,
• and the pharmaceutically acceptable salts thereof

A method for inhibiting matrix metalloproteinase enzymes in a mammal comprising administering an MMP inhibiting amount of a compound of Formula V:

• 31
• wherein n is 0 to 6,
• R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3;
• Aryl is phenyl or substituted phenyl;
• Het is an unsubstituted or substituted heteroaryl group;
• and the pharmaceutically acceptable salts thereof.

A compound having Formula I

• R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3,
• 32
• E is independently O or S;
• A and B independently are OR4 or NR4R5;
• R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted,
• n is an integer from 0 to 6,
• and the pharmaceutically acceptable salts thereof.

A compound selected from

• Pyridine-2,4-dicarboxylic acid bis-(3-methoxy-benzylamide),
• Pyridine-3,5-dicarboxylic acid bis-(4-chloro-benzylamide),
• Pyridine-3,5-dicarboxylic acid bis-(3-chloro-benzylamide);
• 2-Methoxy-pyridine-3,5-dicarboxylic acid bis-[(1,3 -benzodioxol-5-ylmethyl)-amide];
• Pyridine-3,5-dicarboxylic acid bis-(1,3-benzodioxol-5-ylmethyl) ester;.
• Pyridine-3,5-dicarboxylic acid bis-(4-methoxy-benzylamide);,
• Pyridine-3,5-dicarboxylic acid bis-[( 1,3-benzodioxol-5-ylmethyl)-amide];
• Pyridine-2,4-dicarboxylic acid bis-[( 1,3 -benzodioxol-5-ylmethyl)-amide];
• Pyridine-3,5-dicarboxylic acid bis-(4-fluoro-benzylamide);
• Pyridine-3,5-dicarboxylic acid, (4-chloro-benzylamide), [(1,3-benzodioxol-5-ylmethyl)-amide];
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide), [1,3 -benzodioxol-5-ylmethyl)-amide];
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide), (4-methoxy-benzylamide);
• Pyridine-3,5-dicarboxylic acid, (4-carbomethoxy-benzylamide),(3-methoxy-benzylamide);
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide),(3-pyridylmethylamide);
• Pyridine-3,5-dicarboxylic acid, (4-carboxy-benzylamide),(3-thiophenemethylamide);
• Pyridine-3,5-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, [(1,3benzodioxol-5ylmethyl)-amide];
• Pyridine-3,5-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, [(1,3-benzodioxol-5-ylmethyl)-amide];
• Pyridine-3,5-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, [(4-methoxy-benzylamide);
• Pyridine-3,5 -dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, (4-methoxy-benzylamide);
• Pyridine-3,5-dicarboxylic acid bis-(1,3-benzodioxol-5-ylmethyl) ester;
• 2-Methoxy-pyridine-3,5-dicarboxylic acid bis-[(1,3 -benzodioxol-5-ylmethyl)-amide],
• 2-Ethoxy-pyridine-3,5-dicarboxylic acid bis-[(1,3-benzodioxol-5-ylmethyl)-amide];
• and
• 2-Amino-pyridine-)3,5-dicarboxylic acid bis-[(1,3-benzodioxol-5- ylmethyl)-amide].